193 related articles for article (PubMed ID: 20863555)
1. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.
Bae-Jump VL; Zhou C; Boggess JF; Whang YE; Barroilhet L; Gehrig PA
Gynecol Oncol; 2010 Dec; 119(3):579-85. PubMed ID: 20863555
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
Zhou C; Gehrig PA; Whang YE; Boggess JF
Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.
Bae-Jump VL; Zhou C; Gehrig PA; Whang YE; Boggess JF
Gynecol Oncol; 2006 Mar; 100(3):487-94. PubMed ID: 16249016
[TBL] [Abstract][Full Text] [Related]
4. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
[TBL] [Abstract][Full Text] [Related]
5. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
6. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro.
Darb-Esfahani S; Faggad A; Noske A; Weichert W; Buckendahl AC; Müller B; Budczies J; Röske A; Dietel M; Denkert C
J Cancer Res Clin Oncol; 2009 Jul; 135(7):933-41. PubMed ID: 19107520
[TBL] [Abstract][Full Text] [Related]
7. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
Shafer A; Zhou C; Gehrig PA; Boggess JF; Bae-Jump VL
Int J Cancer; 2010 Mar; 126(5):1144-54. PubMed ID: 19688827
[TBL] [Abstract][Full Text] [Related]
9. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.
Zhou C; Bae-Jump VL; Whang YE; Gehrig PA; Boggess JF
Gynecol Oncol; 2006 May; 101(2):305-10. PubMed ID: 16380156
[TBL] [Abstract][Full Text] [Related]
10. Expression of metabolically targeted biomarkers in endometrial carcinoma.
Wahl H; Daudi S; Kshirsagar M; Griffith K; Tan L; Rhode J; Liu JR
Gynecol Oncol; 2010 Jan; 116(1):21-7. PubMed ID: 19878980
[TBL] [Abstract][Full Text] [Related]
11. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.
Cantrell LA; Zhou C; Mendivil A; Malloy KM; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2010 Jan; 116(1):92-8. PubMed ID: 19822355
[TBL] [Abstract][Full Text] [Related]
12. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
Meyer LA; Slomovitz BM; Djordjevic B; Westin SN; Iglesias DA; Munsell MF; Jiang Y; Schmandt R; Broaddus RR; Coleman RL; Galbincea JM; Lu KH
Int J Gynecol Cancer; 2014 May; 24(4):713-7. PubMed ID: 24651628
[TBL] [Abstract][Full Text] [Related]
13. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma.
Shen Q; Stanton ML; Feng W; Rodriguez ME; Ramondetta L; Chen L; Brown RE; Duan X
Int J Clin Exp Pathol; 2010 Nov; 4(1):13-21. PubMed ID: 21228924
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
15. Molecular target therapies in endometrial cancer: from the basic research to the clinic.
Gadducci A; Tana R; Cosio S; Fanucchi A; Genazzani AR
Gynecol Endocrinol; 2008 May; 24(5):239-49. PubMed ID: 18569027
[TBL] [Abstract][Full Text] [Related]
16. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models.
Squillace RM; Miller D; Cookson M; Wardwell SD; Moran L; Clapham D; Wang F; Clackson T; Rivera VM
Mol Cancer Ther; 2011 Oct; 10(10):1959-68. PubMed ID: 21825008
[TBL] [Abstract][Full Text] [Related]
18. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Sivalingam VN; Kitson S; McVey R; Roberts C; Pemberton P; Gilmour K; Ali S; Renehan AG; Kitchener HC; Crosbie EJ
Br J Cancer; 2016 Feb; 114(3):281-9. PubMed ID: 26794276
[TBL] [Abstract][Full Text] [Related]
19. Effects of rapamycin on the mechanistic target of rapamycin (mTOR) pathway and telomerase in breast cancer cells.
Gopalakrishnan K; Venkatesan S; Low ESH; Hande MP
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):103-113. PubMed ID: 30442335
[TBL] [Abstract][Full Text] [Related]
20. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F
Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
